MicroRNA profiling reveals dysregulated microRNAs and their target gene regulatory networks in cemento‐ossifying fibroma

BACKGROUND Cemento-ossifying fibroma (COF) is a benign fibro-osseous neoplasm of uncertain pathogenesis, and its treatment results in morbidity. MicroRNAs (miRNA) are small non-coding RNAs that regulate gene expression and may represent therapeutic targets. The purpose of the study was to generate a comprehensive miRNA profile of COF compared to normal bone. Additionally, the most relevant pathways and target genes of differentially expressed miRNA were investigated by in silico analysis. METHODS Nine COF and ten normal bone samples were included in the study. miRNA profiling was carried out by using TaqMan® OpenArray® Human microRNA panel containing 754 validated human miRNAs. We identified the most relevant miRNAs target genes through the leader gene approach, using STRING and Cytoscape software. Pathways enrichment analysis was performed using DIANA-miRPath. RESULTS Eleven miRNAs were downregulated (hsa-miR-95-3p, hsa-miR-141-3p, hsa-miR-205-5p, hsa-miR-223-3p, hsa-miR-31-5p, hsa-miR-944, hsa-miR-200b-3p, hsa-miR-135b-5p, hsa-miR-31-3p, hsa-miR-223-5p and hsa-miR-200c-3p), and five were upregulated (hsa-miR-181a-5p, hsa-miR-181c-5p, hsa-miR-149-5p, hsa-miR-138-5p and hsa-miR-199a-3p) in COF compared to normal bone. Eighteen common target genes were predicted, and the leader genes approach identified the following genes involved in human COF: EZH2, XIAP, MET and TGFBR1. According to the biology of bone and COF, the most relevant KEGG pathways revealed by enrichment analysis were proteoglycans in cancer, miRNAs in cancer, pathways in cancer, p53-, PI3K-Akt-, FoxO- and TGF-beta signalling pathways, which were previously found to be differentially regulated in bone neoplasms, odontogenic tumours and osteogenesis. CONCLUSION miRNA dysregulation occurs in COF, and EZH2, XIAP, MET and TGFBR1 are potential targets for functional analysis validation.

[1]  Leilei Zheng,et al.  Runx2 alleviates high glucose‐suppressed osteogenic differentiation via PI3K/AKT/GSK3β/β‐catenin pathway , 2017, Cell biology international.

[2]  Fengbo Guo,et al.  TEAD1 mediates the oncogenic activities of Hippo-YAP1 signaling in osteosarcoma. , 2017, Biochemical and biophysical research communications.

[3]  Laércio Ives Santos,et al.  An adaptation of particle swarm clustering applied in basal cell carcinoma, squamous cell carcinoma of the skin and actinic keratosis , 2017 .

[4]  Abudusaimi Aimaiti,et al.  NRSN2 promotes osteosarcoma cell proliferation and growth through PI3K/Akt/MTOR and Wnt/β-catenin signaling. , 2017, American journal of cancer research.

[5]  John M. Wright,et al.  Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Odontogenic and Maxillofacial Bone Tumors , 2017, Head and Neck Pathology.

[6]  Wenyan Zhang,et al.  MicroRNA-520b Suppresses Proliferation, Migration, and Invasion of Spinal Osteosarcoma Cells via Downregulation of Frizzled-8. , 2017, Oncology research.

[7]  Minoru Kanehisa,et al.  KEGG: new perspectives on genomes, pathways, diseases and drugs , 2016, Nucleic Acids Res..

[8]  C. Marshall,et al.  Mutations Preventing Regulated Exon Skipping in MET Cause Osteofibrous Dysplasia. , 2015, American journal of human genetics.

[9]  Hsien-Da Huang,et al.  miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database , 2015, Nucleic Acids Res..

[10]  J. Yue,et al.  FOXO1 inhibits osteosarcoma oncogenesis via Wnt/β-catenin pathway suppression , 2015, Oncogenesis.

[11]  John G Flannery,et al.  Neuron-glia signaling in developing retina mediated by neurotransmitter spillover , 2015, eLife.

[12]  Rui-peng Song,et al.  P53 suppresses cell proliferation, metastasis, and angiogenesis of osteosarcoma through inhibition of the PI3K/AKT/mTOR pathway. , 2015, International journal of surgery.

[13]  D. Bartel,et al.  Predicting effective microRNA target sites in mammalian mRNAs , 2015, eLife.

[14]  H. Mankin,et al.  CD44 is a direct target of miR-199a-3p and contributes to aggressive progression in osteosarcoma , 2015, Scientific Reports.

[15]  Junfeng Zhang,et al.  Identification of miR-199a-5p in serum as noninvasive biomarkers for detecting and monitoring osteosarcoma , 2015, Tumor Biology.

[16]  A. Guimarães,et al.  Bioinformatics, interaction network analysis, and neural networks to characterize gene expression of radicular cyst and periapical granuloma. , 2015, Journal of endodontics.

[17]  Artemis G. Hatzigeorgiou,et al.  DIANA-miRPath v3.0: deciphering microRNA function with experimental support , 2015, Nucleic Acids Res..

[18]  N. Itoh,et al.  The Fibroblast Growth Factor signaling pathway , 2015, Wiley interdisciplinary reviews. Developmental biology.

[19]  T. Cheng,et al.  TGF-β1 Promotes Osteosarcoma Cell Migration and Invasion Through the miR-143-Versican Pathway , 2014, Cellular Physiology and Biochemistry.

[20]  H. Coleman,et al.  A clinico-pathologic review of 56 cases of ossifying fibroma of the jaws with emphasis on the histomorphologic variations. , 2014, Nigerian journal of clinical practice.

[21]  E. Erdal,et al.  MiR-181a-5p is downregulated in hepatocellular carcinoma and suppresses motility, invasion and branching-morphogenesis by directly targeting c-Met. , 2014, Biochemical and biophysical research communications.

[22]  Zhonghan Li,et al.  Therapeutic targeting of microRNAs: current status and future challenges , 2014, Nature Reviews Drug Discovery.

[23]  Jay R. Hesselberth,et al.  HITS-CLIP reveals key regulators of nuclear receptor signaling in breast cancer , 2014, Breast Cancer Research and Treatment.

[24]  A. Bhinge,et al.  MiR‐135b is a direct PAX6 target and specifies human neuroectoderm by inhibiting TGF‐β/BMP signaling , 2014, The EMBO journal.

[25]  G. Palù,et al.  Characterization of a New CDC73 Missense Mutation that Impairs Parafibromin Expression and Nucleolar Localization , 2014, PloS one.

[26]  R. Jordan,et al.  Erratum to: Fibro-Osseous Lesions of the Craniofacial Bones: β-Catenin Immunohistochemical Analysis and CTNNB1 and APC Mutation Analysis , 2014, Head and Neck Pathology.

[27]  Jay R. Hesselberth,et al.  Genome‐Wide Analysis of miRNA‐mRNA Interactions in Marrow Stromal Cells , 2014, Stem cells.

[28]  A. Cleton-Jansen,et al.  Recurrent Chromosome 22 Deletions in Osteoblastoma Affect Inhibitors of the Wnt/Beta-Catenin Signaling Pathway , 2013, PloS one.

[29]  Peilin Jia,et al.  Association Study of 167 Candidate Genes for Schizophrenia Selected by a Multi-Domain Evidence-Based Prioritization Algorithm and Neurodevelopmental Hypothesis , 2013, PloS one.

[30]  P. Robinson,et al.  miR-181a promotes osteoblastic differentiation through repression of TGF-β signaling molecules. , 2013, The international journal of biochemistry & cell biology.

[31]  R. Carlos,et al.  Assessing the contribution of HRPT2 to the pathogenesis of jaw fibrous dysplasia, ossifying fibroma, and osteosarcoma. , 2013, Oral surgery, oral medicine, oral pathology and oral radiology.

[32]  Weikai Zhang,et al.  miR‑142‑3p promotes osteoblast differentiation by modulating Wnt signaling. , 2013, Molecular medicine reports.

[33]  A. Chinnaiyan,et al.  Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma , 2012, Oncotarget.

[34]  Yali Hu,et al.  MicroRNA‐181a Regulates Local Immune Balance by Inhibiting Proliferation and Immunosuppressive Properties of Mesenchymal Stem Cells , 2012, Stem cells.

[35]  Jian-yong Li,et al.  miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. , 2012, Carcinogenesis.

[36]  Kevin B. Jones,et al.  miRNA signatures associate with pathogenesis and progression of osteosarcoma. , 2012, Cancer research.

[37]  B. Jiang,et al.  miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP , 2012, Cancer Chemotherapy and Pharmacology.

[38]  Yi Jin,et al.  MicroRNA-138 suppresses epithelial-mesenchymal transition in squamous cell carcinoma cell lines. , 2011, The Biochemical journal.

[39]  A. Khademhosseini,et al.  Controlling the fibroblastic differentiation of mesenchymal stem cells via the combination of fibrous scaffolds and connective tissue growth factor. , 2011, Tissue engineering. Part A.

[40]  G. Requirand,et al.  Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration. , 2011, Blood.

[41]  Tao Wang,et al.  miR-27 promotes osteoblast differentiation by modulating Wnt signaling. , 2010, Biochemical and biophysical research communications.

[42]  N. Baldini,et al.  Gene expression patterns related to osteogenic differentiation of bone marrow-derived mesenchymal stem cells during ex vivo expansion. , 2010, Tissue engineering. Part C, Methods.

[43]  D. Macdonald-Jankowski,et al.  Ossifying fibroma: a systematic review. , 2009, Dento maxillo facial radiology.

[44]  Ji Young Kim,et al.  MicroRNA miR-199a* Regulates the MET Proto-oncogene and the Downstream Extracellular Signal-regulated Kinase 2 (ERK2)* , 2008, Journal of Biological Chemistry.

[45]  C. Chiang,et al.  Central ossifying fibroma: a clinicopathologic study of 28 cases. , 2008, Journal of the Formosan Medical Association = Taiwan yi zhi.

[46]  Bin Tean Teh,et al.  HRPT2 gene alterations in ossifying fibroma of the jaws. , 2006, Oral oncology.

[47]  Shaun K Olsen,et al.  Receptor Specificity of the Fibroblast Growth Factor Family , 2006, Journal of Biological Chemistry.

[48]  Michael W Pfaffl,et al.  RNA integrity and the effect on the real-time qRT-PCR performance. , 2006, Molecular aspects of medicine.

[49]  Martin Kuiper,et al.  BiNGO: a Cytoscape plugin to assess overrepresentation of Gene Ontology categories in Biological Networks , 2005, Bioinform..

[50]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[51]  Hengbin Wang,et al.  Role of Histone H3 Lysine 27 Methylation in X Inactivation , 2003, Science.

[52]  Huilin Qi,et al.  Identification of genes responsible for osteoblast differentiation from human mesodermal progenitor cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[53]  Hengbin Wang,et al.  Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing , 2002, Science.

[54]  R. Brannon,et al.  Benign Fibro-Osseous Lesions: A Review of Current Concepts , 2001, Advances in anatomic pathology.

[55]  D. Weathers,et al.  Distinguishing features of focal cemento-osseous dysplasias and cemento-ossifying fibromas: I. A pathologic spectrum of 316 cases. , 1997, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[56]  Guy S. Salvesen,et al.  X-linked IAP is a direct inhibitor of cell-death proteases , 1997, Nature.

[57]  V. Ambros,et al.  The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 , 1993, Cell.

[58]  K. Miyazono,et al.  Cloning of a TGFβ type I receptor that forms a heteromeric complex with the TGFβ type II receptor , 1993, Cell.

[59]  R. Norum,et al.  Hereditary hyperparathyroidism and multiple ossifying jaw fibromas: a clinically and genetically distinct syndrome. , 1990, Surgery.

[60]  L. R. Eversole,et al.  Ossifying fibroma: a clinicopathologic study of sixty-four cases. , 1985, Oral surgery, oral medicine, and oral pathology.

[61]  R. Jordan,et al.  Fibro-Osseous Lesions of the Craniofacial Bones: β-Catenin Immunohistochemical Analysis and CTNNB1 and APC Mutation Analysis , 2014 .

[62]  L. Barnes,et al.  Pathology and genetics of head and neck tumours , 2005 .

[63]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[64]  J. Rowley,et al.  The human met oncogene is related to the tyrosine kinase oncogenes , 1985, Nature.